Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients

References

• Lader M. Benzodiazepines revisited - will we ever learn? Addiction. 2011;106:2086–2109.
   PubMed Web of Science ®Google Scholar
• Alessi-Severini S, Bolton JM, Enns MW, et al. Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open. 2014;2:e208–e216.
   PubMedGoogle Scholar
• Victorri-Vigneau C, Dailly E, Veyrac G, et al. Evidence of zolpidem abuse and dependence: results of the French centre for evaluation and information on pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64:198–209.
   PubMed Web of Science ®Google Scholar
• Victorri-Vigneau C, Gérardin M, Rousselet M, et al. An update on zolpidem abuse and dependence. J Addict Dis. 2014;33:15–23.
   PubMed Web of Science ®Google Scholar
• Wen YP, Shieh MJ, Lin HC, et al. High-dose and long-term users of hypnotic and sedative drugs among taiwanese outpatients: prevalence and correlates from a population-based analysis. Br J Med Med Res. 2014;4:1577–1590.
   Google Scholar
• Yen CF, Yen CN, Ko CH, et al. Correlates of dependence and beliefs about the use of hypnotics among zolpidem and zopiclone users. Subst Use Misuse. 2015;50:350–357.
   PubMed Web of Science ®Google Scholar
• Hansen RN, Boudreau DM, Ebel BE, et al. Sedative hypnotic medication use and the risk of motor vehicle crash. Am J Public Health. 2015;105:e64–69.
   PubMed Web of Science ®Google Scholar
• Lai MM, Lin CC, Lin CC, et al. Long-term use of zolpidem increases the risk of major injury: a population-based cohort study. Mayo Clin Proc. 2014;89:589–594.
   PubMed Web of Science ®Google Scholar
• Darke S, Deady M, Duflou J. Toxicology and characteristics of deaths involving zolpidem in New South Wales, Australia 2001–2010. J Forensic Sci. 2012;57:1259–1262.
   PubMed Web of Science ®Google Scholar
• Lee D, Delcher C, Maldonado-Molina MM, et al. Trends in licit and illicit drug-related deaths in Florida from 2001 to 2012. Forensic Sci Int. 2014;245:178–186.
   PubMed Web of Science ®Google Scholar
• Allain H, Le Coz F, Borderies P, et al. Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia. Hum Psychopharmacol. 1998;13:551–559.
   Web of Science ®Google Scholar
• Jembrek MJ, Vlainić J, Šuran J. Zolpidem withdrawal induced uncoupling of GABA(A) receptors in vitro associated with altered GABA(A) receptor subunit mRNA expression. Acta Neurobiol. 2015;75:160–171.
   PubMed Web of Science ®Google Scholar
• Hajak G, Müller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98:1371–1378.
   PubMed Web of Science ®Google Scholar
• Pollmann AS, Murphy AL, Bergman JC, et al. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol. 2015;16:19.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime (UNODC). 2001. CND Dec.44/4. Inclusion of zolpidem (INN) in Schedule IV of the 1971 Convention on Psychotropic Substances. [cited 2019 Feb 21]. Available at: https://www.unodc.org/unodc/en/Resolutions/resolution_2001-03-20_4.html.
   Google Scholar
• Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64:339–351.
   PubMed Web of Science ®Google Scholar
• Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59:865–889.
   PubMed Web of Science ®Google Scholar
• Soyka M, Bottlender R, Möller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry. 2000;33:138–141.
   PubMed Web of Science ®Google Scholar
• Schifano F, Chiappini S, Corkery JM, et al. An insight into Z-drugs abuse and dependence: an examination of reports to the European Medicines Agency (EMA) database of suspected adverse drug reactions (ADR). Int J Neuropsychopharmacol. 2019;Feb 5 doi:10.1093/ijnp/pyz007
   PubMed Web of Science ®Google Scholar
• Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med. 2018;178:1275–1277.
   PubMed Web of Science ®Google Scholar
• García-Cortés M, Ortega-Alonso A, Lucena MI, et al. Drug-induced liver injury: a safety review. Expert Opin Drug Saf. 2018;17:795–804.
   PubMed Web of Science ®Google Scholar
• Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767–777.
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003–2009.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63:590–603.
   PubMed Web of Science ®Google Scholar
• Lugoboni F, Mirijello A, Morbioli L, et al. Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine monoabusers. Expert Opin Drug Saf. 2018;17:451–456.
   PubMed Web of Science ®Google Scholar
• Pichard L, Gillet G, Bonfils C, et al. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab Dispos. 1995;23:1253–1262.
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol. 1999;48:89–97.
   PubMed Web of Science ®Google Scholar
• Berson A, Descatoire V, Sutton A, et al. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther. 2001;299:793–800.
   PubMed Web of Science ®Google Scholar
• Quaglio G, Pattaro C, Gerra G, et al. High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam. Psychiatry Res. 2012;198:457–462.
   PubMed Web of Science ®Google Scholar
• Lugoboni F, Mirijello A, Faccini M, et al. Quality of life in a cohort of high-dose benzodiazepine dependent patients. Drug Alcohol Depend. 2014;142:105–109.
   PubMed Web of Science ®Google Scholar
• Faccini M, Leone R, Opri S, et al. Slow subcutaneous infusion of flumazenil for the treatment of long- term, high-dose benzodiazepine users: a review of 214 cases. J Psychopharmacol. 2016;30:1047–1053.
   PubMed Web of Science ®Google Scholar
• Hood SD, Norman A, Hince DA, et al. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol. 2014;77:285–294.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th. American Psychiatric Press: Washington (DC); 2000. (text revision).
   Google Scholar
• American Psychiatric Association. Diagnostic and statisticalmanual of mental disorders. 5th ed. Arlington: Am Psychiatr Assoc; 2013.
   Google Scholar
• Janhsen K, Roser P, Hoffmann K. The problems of long-term treatment with benzodiazepines and related substances. Dtsch Arztebl Int. 2015;112:1–7.
   PubMed Web of Science ®Google Scholar
• Liebrenz M, Boesch L, Stohler R, et al. Agonist substitution – a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction. 2010;105:1870–1874.
   PubMed Web of Science ®Google Scholar
• Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272–276.
   PubMed Web of Science ®Google Scholar
• Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89:327–334.
   PubMed Web of Science ®Google Scholar
• Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–1370.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–815.
   PubMed Web of Science ®Google Scholar
• Galanter M, Kleber HD. The American Psychiatric publishing textbook of substance abuse treatment. 4th ed. Washington, DC: American Psychiatric Publishing; 2008.
   Google Scholar
• Cubała WJ, Landowski J. Seizure following sudden zolpidem withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:539–540.
   PubMed Web of Science ®Google Scholar
• Haji Seyed Javadi SA, Hajiali F, Nassiri-Asl M. Zolpidem dependency and withdrawal seizure: a case report study. Iran Red Crescent Med J. 2014;16:e19926.
   PubMed Web of Science ®Google Scholar
• Rousselet M, Feuillet F, Gerardin M, et al. The French addictovigilance network clinical assessment: Z-drugs, true false twins. Expert Opin Drug Saf. 2017;16:1063–1069.
   PubMed Web of Science ®Google Scholar
• Jang Y, Song I, Oh IS, et al. Twelve-year trend in the use of zolpidem and physicians’ non-compliance with recommended duration: a Korean national health insurance database study. Eur J Clin Pharmacol. 2019;75:109–117.
   PubMed Web of Science ®Google Scholar
• OSMED (National Observatory on the Use of Medicines), 2014. L’uso dei farmaci in Italia. [cited 2015 Dec 24]. http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2014_0.pdf
   Google Scholar
• Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology. 2005;41:1151–1159.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the dionysos study. Hepatology. 1994;20:1442–1449.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.e1.
   PubMed Web of Science ®Google Scholar
• Karsenti D, Blanc P, Bacq Y, et al. Hepatotoxicity associated with zolpidem treatment. Bmj. 1999 May;1(318):1179.
   Google Scholar
• Jouanjus E, Guernec G, Lapeyre-Mestre M, et al. Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion. Fundam Clin Pharmacol. 2018;32:306–322.
   PubMed Web of Science ®Google Scholar
• Moore N, Pariente A, Bégaud B. Why are benzodiazepines not yet controlled substances? JAMA Psychiatry. 2015;72:110–111.
   PubMed Web of Science ®Google Scholar
• Petitjean S, Ladewig D, Meier CR, et al. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol. 2007;22:292–298.
   PubMed Web of Science ®Google Scholar
• Kapil V, Green JL, Le Lait C, et al. Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatry. 2014;205:407–408.
   PubMed Web of Science ®Google Scholar